Macquarie has maintained an ‘outperform’ rating on Solara Pharma, raising its target price to Rs 2,112. The firm has also added the stock to the 'Asia Pacific Marquee Buy' list.
According to Macquarie, the key catalyst for Solara Pharma is the Vizag facility reaching its optimum utilisation in Q1 of FY22.
Watch the accompanying video of CNBC-TV18’s Nimesh Shah for more details.
To watch other videos in this series, click on the Standout Brokerage Report tab below.
Disclaimer: The views and investment tips expressed are not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
(Edited by : Niral Sharma)
First Published: IST